Stephen P. Robertson sold $975k of AUPH
EVP, General Counsel at Aurinia Pharmaceuticals Inc.. 122,479 shares at an average of $7.96, traded Mar 3, 2025, filed Mar 4, 2025.
Score components
- +15RoleOfficer
- +25Trade size$975k at market
- +5Share of holdings soldSold 19% of holdings
- +15Cluster5 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001600620-25-000019, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 28, 2025 | AGrant or award Common Stock | +84,106 | $0.00 | $0 | 529,349 | Mar 4, 2025 |
| Mar 3, 2025 | AGrant or award Common Stock | +102,406 | $0.00 | $0 | 631,755 | Mar 4, 2025 |
| Mar 3, 2025 | SOpen-market sale Common Stock | -64,872 | $8.00 | $519k | 566,883 | Mar 4, 2025 |
| Mar 4, 2025 | SOpen-market sale Common Stock | -57,607 | $7.92 | $456k | 509,276 | Mar 4, 2025 |
| Feb 28, 2025 | AGrant or award Employee Stock Option (right to buy)derivative | +128,438 | $0.00 | $0 | 128,438 | Mar 4, 2025 |
Related signals
Other insiders at Aurinia Pharmaceuticals Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 27Weak | AUPHsell Aurinia Pharmaceuticals Inc. | Stephen P. Robertson Chief Legal Officer | $190k 11,939 shares | -2% | |
| 43Moderate | AUPHbuy Aurinia Pharmaceuticals Inc. | Kevin Tang director | $14M 1,300,000 shares | +13% | |
| 32Weak | AUPHsell Aurinia Pharmaceuticals Inc. | Greg Keenan Chief Medical Officer | $210k 20,000 shares | -13% | |
| 38Weak | Aurinia Pharmaceuticals Inc. | Greg Keenan Chief Medical Officer | $68k 8,305 shares | -5% | |
| 48Moderate | AUPHbuy Aurinia Pharmaceuticals Inc. | Kevin Tang director | $13M 1,600,000 shares | +19% | |
| 65Notable | Aurinia Pharmaceuticals Inc. | Matthew Maxwell Donley Chief Operating Officer | $994k 124,893 shares | -16% | |
| 66Notable | Aurinia Pharmaceuticals Inc. | Joseph M Miller Chief Financial Officer | $940k 118,013 shares | -17% | |
| 40Moderate | Aurinia Pharmaceuticals Inc. | Greg Keenan Chief Medical Officer | $98k 12,239 shares | -7% | |
| 70Notable | Aurinia Pharmaceuticals Inc. | Peter Greenleaf Chief Executive Officer | $2.9M 360,540 shares | -17% | |
| 43Moderate | AUPHbuy Aurinia Pharmaceuticals Inc. | Kevin Tang director | $11M 1,200,000 shares | +17% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.